

8 April 2025

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

Dear Madam

Successful Completion of the Entitlement Offer

Biotron Limited (ASX: BIT, **Biotron** or **the Company**) is pleased to announce that the renounceable rights issue announced on 28 February 2025 has closed, raising \$1,274,589 (before costs). The Company will issue 424,863,077 new fully paid ordinary shares (**Shares**).

The Company would like to thank all shareholders for their support of the rights issue, particularly in these difficult times, and would like to welcome new investors to the register.

It is noted that the Company's Directors and management took up their entitlements in full, demonstrating strong commitment to the Company and confidence in its future.

The final allocations are set out below:

	Funds Raised	Shares Issued
Rights taken up	\$668,336	222,778,637
Shortfall	\$606,253	202,084,440
Total	\$1,274,589	424,863,077

As set out in the Prospectus for the offer, the net proceeds will enable the Company to continue commercialisation activities focused on achieving strategic partnership(s) for its portfolio of antiviral programs including its lead asset BIT225, expand its promising early stage Hepatitis B virus program, and support ongoing administration and operational costs.

Mahe Capital Pty Ltd acted as Lead Manager and Underwriter to the rights issue.

The new securities will be issued on Tuesday, 8 April 2025, in accordance with the timetable in the prospectus. The Directors and the Lead Manager reserve the right to place any shortfall shares at their discretion within 3 months of the closing date.

This Announcement has been approved for release by the Board of Directors.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn12585

Enquiries:

Dr Michelle Miller
Managing Director
Biotron Limited
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333

For personal use only